With regard to medication, the proportions of using β‐blockers (P = 0.004) and GP IIb/IIIa inhibitors (P = 0.035) were significantly higher in the BP-DES group than in the G2-DES group in patients with DM. The gene discussed is ITGA2B; the disease is diabetes mellitus.